NeuroControl

One of the saddest stories I’ve read about the brave new world of medtech:

Lacking momentum, NeuroControl stopped selling the product. “The investors had expected that it would penetrate a much larger volume of the overall spinal-injury population,” says Geoff Thrope, who was NeuroControl’s director of business development. “We were able to make dozens of implant sales per year. You need to be in the hundreds, if not thousands, to have it make sense.”

 

The market gives and the market takes away.